title: Rituximab for myasthenia gravis developing after bone marrow transplant.
authors.affiliation: Department of Clinical and Morphological Research, University Hospital and School of Medicine, Udine, Italy. Ematologia@drmm.uniud.it
authors.forename: F
authors.initials: F
authors.lastname: Zaja
authors.forename: D
authors.initials: D
authors.lastname: Russo
authors.forename: G
authors.initials: G
authors.lastname: Fuga
authors.forename: G
authors.initials: G
authors.lastname: Perella
authors.forename: M
authors.initials: M
authors.lastname: Baccarani
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D016026:Bone Marrow Transplantation; D006801:Humans; D008297:Male; D009157:Myasthenia Gravis / Q000188:drug therapy*; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab